EA201690788A1 - Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат - Google Patents

Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат

Info

Publication number
EA201690788A1
EA201690788A1 EA201690788A EA201690788A EA201690788A1 EA 201690788 A1 EA201690788 A1 EA 201690788A1 EA 201690788 A EA201690788 A EA 201690788A EA 201690788 A EA201690788 A EA 201690788A EA 201690788 A1 EA201690788 A1 EA 201690788A1
Authority
EA
Eurasian Patent Office
Prior art keywords
olat
triazol
pyrimidin
pyrazole
containing sodium
Prior art date
Application number
EA201690788A
Other languages
English (en)
Other versions
EA032932B1 (ru
Inventor
Хайке Нойманн
Клаус Бенке
Михаель Формелль
Габриеле Винтер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690788(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201690788A1 publication Critical patent/EA201690788A1/ru
Publication of EA032932B1 publication Critical patent/EA032932B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение касается твердых, применимых перорально фармацевтических лекарственных форм, содержащих натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1H-1,2,3-триазол-1-ил)-1H-пиразол-5-олат (биологически активное вещество (I)), отличающихся тем, что высвобождается биологически активное вещество (I), а также способа их получения, их применения в качестве лекарственного средства, а также их применения для профилактики, вторичной профилактики или лечения заболеваний, в частности заболеваний сердечно-сосудистой системы, сердечной недостаточности, анемии, хронических заболеваний почек и почечной недостаточности.
EA201690788A 2013-10-17 2014-10-13 Лекарственная форма, содержащая натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат, и способ ее получения EA032932B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13189145 2013-10-17
PCT/EP2014/071855 WO2015055564A1 (de) 2013-10-17 2014-10-13 Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat

Publications (2)

Publication Number Publication Date
EA201690788A1 true EA201690788A1 (ru) 2016-09-30
EA032932B1 EA032932B1 (ru) 2019-08-30

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690788A EA032932B1 (ru) 2013-10-17 2014-10-13 Лекарственная форма, содержащая натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат, и способ ее получения

Country Status (35)

Country Link
US (1) US9827198B2 (ru)
EP (1) EP3057580B1 (ru)
JP (1) JP6525979B2 (ru)
KR (1) KR102330953B1 (ru)
CN (1) CN105636580B (ru)
AP (1) AP2016009135A0 (ru)
AR (1) AR098064A1 (ru)
AU (1) AU2014336389B2 (ru)
BR (1) BR112016007588A2 (ru)
CA (1) CA2927437C (ru)
CL (1) CL2016000857A1 (ru)
CU (1) CU24515B1 (ru)
DK (1) DK3057580T3 (ru)
DO (1) DOP2016000078A (ru)
EA (1) EA032932B1 (ru)
ES (1) ES2868228T3 (ru)
GT (1) GT201600072A (ru)
HR (1) HRP20210691T1 (ru)
HU (1) HUE054107T2 (ru)
IL (1) IL244933B (ru)
JO (1) JO3645B1 (ru)
LT (1) LT3057580T (ru)
MA (1) MA38974B2 (ru)
MX (1) MX2016004628A (ru)
MY (1) MY190202A (ru)
NI (1) NI201600054A (ru)
PE (1) PE20160669A1 (ru)
PH (1) PH12016500716A1 (ru)
SA (1) SA516370940B1 (ru)
SI (1) SI3057580T1 (ru)
TN (1) TN2016000135A1 (ru)
TW (1) TWI746418B (ru)
UA (1) UA119855C2 (ru)
UY (1) UY35784A (ru)
WO (1) WO2015055564A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020045607A1 (ja) * 2018-08-31 2020-03-05 アステラス製薬株式会社 経口投与用医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
EP2133096A4 (en) * 2007-03-13 2011-11-16 Dainippon Sumitomo Pharma Co IN THE MOUTHING TABLET
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
UY35784A (es) 2015-05-29
CU24515B1 (es) 2021-05-12
CN105636580A (zh) 2016-06-01
CA2927437A1 (en) 2015-04-23
PH12016500716B1 (en) 2016-06-20
TWI746418B (zh) 2021-11-21
CA2927437C (en) 2022-06-28
JO3645B1 (ar) 2020-08-27
KR20160068784A (ko) 2016-06-15
PE20160669A1 (es) 2016-08-04
CN105636580B (zh) 2020-03-31
HRP20210691T1 (hr) 2021-06-11
ES2868228T3 (es) 2021-10-21
EP3057580A1 (de) 2016-08-24
CL2016000857A1 (es) 2016-11-25
AU2014336389A1 (en) 2016-05-12
EA032932B1 (ru) 2019-08-30
MA38974B2 (fr) 2020-11-30
JP2016538256A (ja) 2016-12-08
NI201600054A (es) 2016-09-21
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
CU20160048A7 (es) 2016-10-28
PH12016500716A1 (en) 2016-06-20
US9827198B2 (en) 2017-11-28
GT201600072A (es) 2018-12-19
EP3057580B1 (de) 2021-02-24
TN2016000135A1 (en) 2017-10-06
BR112016007588A2 (pt) 2017-09-12
JP6525979B2 (ja) 2019-06-05
DOP2016000078A (es) 2016-08-15
IL244933B (en) 2020-11-30
MX2016004628A (es) 2016-08-01
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27
WO2015055564A1 (de) 2015-04-23
US20160256394A1 (en) 2016-09-08
TW201607568A (zh) 2016-03-01
SI3057580T1 (sl) 2021-07-30
HUE054107T2 (hu) 2021-08-30
IL244933A0 (en) 2016-05-31
NZ718063A (en) 2021-06-25
LT3057580T (lt) 2021-04-12
DK3057580T3 (da) 2021-05-10
KR102330953B1 (ko) 2021-11-26
MA38974A1 (fr) 2017-05-31
AU2014336389B2 (en) 2020-01-30
MY190202A (en) 2022-04-04

Similar Documents

Publication Publication Date Title
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
EA201100032A1 (ru) Соединения пиридина
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201500293A1 (ru) Антихолинэргическая нейропротективная композиция и способы
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EA201390703A1 (ru) Замещенный натрий-1н-пиразол-5-олат
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201690788A1 (ru) Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
RU2020120876A (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
RU2013127881A (ru) Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM